Home›Stock Screener›Sudeep Pharma›Financial Statements

Sudeep Pharma Complete Financial Statements

7 Years of Data
2026 - 2020

In FY2026, Sudeep Pharma (SUDEEPPHRM) reported revenue ₹189 Cr, net profit ₹49 Cr and EPS ₹4.38, with a net profit margin of 25.9% and ROE of 5.5%. Full financial statements from FY2020 to FY2026 (7 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see Sudeep Pharma screener.

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 25.93% 2026 data
EBITDA Margin 36.51% 2026 data
Operating Margin 34.00% 2026 data
Return on Assets 4.17% 2026 data
Return on Equity 5.55% 2026 data

Balance Sheet Ratios

Current Ratio 8.32 2026 data
Equity Ratio 75.15% 2026 data
Asset Turnover 0.16 2026 data

SUDEEPPHRM Revenue, Net Profit & EBITDA — Year-on-Year Growth

SUDEEPPHRM YoY (Mar 2025 vs Mar 2026) — revenue +17.4%, net profit +11.4%, EBITDA +9.5%, expenses +21.2%. Examine SUDEEPPHRM Q4 results for recent quarterly revenue, profit and EPS trends.

Revenue Growth
+17.4%
Year-over-Year
Net Profit Growth
+11.4%
Year-over-Year
EBITDA Growth
+9.5%
Year-over-Year
Expense Growth
+21.2%
Year-over-Year
Assets Growth
+63.9%
Year-over-Year
Equity Growth
+79.1%
Year-over-Year
Operating Cash Flow Growth
-25.8%
Year-over-Year
Investing Cash Flow Growth
-61.2%
Year-over-Year
Financing Cash Flow Growth
+507.7%
Year-over-Year

SUDEEPPHRM Income Statement — Revenue, EBITDA & Net Profit

Sudeep Pharma revenue ₹189 Cr, EBITDA ₹69 Cr, net profit ₹49 Cr, EPS ₹4.38 (2026) — net profit margin 25.9%. Analyse SUDEEPPHRM shareholder distribution to track promoter, FII and institutional holdings.

Periods ₹ Crores
Particulars Mar 2026 Sept 2025 Mar 2025 Jun 2025 Dec 2025 Sept 2024 Jun 2024 Dec 2024
Revenue 189 173 161 130 179 151 81 118
Expenses 120 107 99 81 112 85 52 76
EBITDA 69 66 63 49 67 65 30 42
Operating Profit Margin % 34.00% 34.00% 37.00% 35.00% 35.00% 43.00% 35.00% 34.00%
Depreciation 4 4 3 3 4 3 3 3
Interest 2 2 2 2 1 1 2 1
Profit Before Tax 63 60 58 44 62 62 26 38
Tax 14 13 14 13 14 13 9 9
Net Profit 49 47 44 31 48 49 17 29
Earnings Per Share (₹) 4.38 4.20 4.07 2.84 4.29 4.49 4.49 2.65

SUDEEPPHRM Balance Sheet — Assets, Liabilities & Shareholders' Equity

SUDEEPPHRM total assets ₹1,175 Cr, total equity ₹883 Cr, total liabilities ₹ Cr (2026) — ROE 5.5%.

Years Annual Data ₹ Crores
Particulars 2026 2025 2024 2023 2022 2021 2020
ASSETS
Total Assets 1,175 717 514 420 344 213 131
Current Assets 624 424 275 230 197 100 56
Fixed Assets 454 189 180 158 137 68 60
Capital Work in Progress 178 88 45 26 8 24 8
Investments 216 0 0 3 0 0 0
Other Assets 0 440 289 233 199 121 63
LIABILITIES
Total Liabilities
Current Liabilities 75 49 21 26 34 19 13
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 883 493 356 223 163 114 81
Share Capital 11 12 1 1 1 1 1
Reserves & Surplus 872 481 355 222 162 113 80

SUDEEPPHRM Cash Flow Statement — Operating, Investing & Financing

Sudeep Pharma operating cash flow ₹49 Cr, investing ₹-79 Cr, financing ₹53 Cr, net cash flow ₹23 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020
Operating Activities 49 66 48 -3 35 10
Investing Activities -79 -49 -50 -38 -40 -23
Financing Activities 53 -13 -10 51 13 12
Net Cash Flow 23 4 -11 10 8 0